Popular weight loss drugs linked to increased hair loss risk, study finds

New research indicates that widely used medications for type 2 diabetes and obesity may lead to hair loss. The study, published in the medical journal 'BMJ', specifically examined GLP-1 receptor agonists, such as semaglutide and tirzepatide, identifying a connection to an elevated risk of alopecia.

Scientists from the University of Pennsylvania and other U.S. institutions analyzed electronic health records of patients with type 2 diabetes. They compared the frequency of hair loss among adults initiating treatment with GLP-1 receptor agonists against those using other antidiabetic drugs, namely SGLT-2 inhibitors and DPP-4 inhibitors. The analysis covered data from January 2019 to September 2024.

The findings revealed that patients using GLP-1 receptor agonists had a 37% higher risk of hair loss compared to those on SGLT-2 inhibitors and a 68% higher risk compared to those on DPP-4 inhibitors. This association was particularly noted for non-scarring alopecia, where hair follicles remain intact, suggesting potential for regrowth. The study also pointed out that patients on GLP-1 receptor agonists typically had a higher baseline Body Mass Index (BMI), and these drugs are known to facilitate rapid weight loss, a documented cause of hair loss.

Although the risk is considered low, researchers emphasize that this knowledge can aid patients and healthcare providers in making more informed treatment decisions. The potential side effect warrants consideration, especially given the popularity and efficacy of these drugs in managing diabetes and obesity.